THERAPEUTICS
ANALONA
Committed to revolutionizing the treatment of pancreatic cancer with innovative new therapies
OUR STORY
Innovating Tomorrow's Pancreatic Cancer Solutions
Founded in 2024, based on our top tier pancreatic cancer research, which has identified a range of novel targets and mechanisms of action.
Analona Therapeutics discover and develop antibody based therapeutics against these targets with an initial focus on a key interactor and facilitator of metabolite transporters.
OUR TEAM
Meet Our Team
Foto: Esben Zøllner Olesen for BioInnovation Institute
Mikkel Wandahl Pedersen
Chief Executive Officer
20 years of experience within biologics drug discovery and development from Symphogen, Servier and Nykode Therapeutics
Axel Behrens
Chief Scientific Officer
Professor, serial entrepreneur and internationally recognized expert in cancer stem cell biology
GET IN TOUCH
